Top

Published in:

01-06-2020 | Colchicine | Case Report

Sustained hypoglycemia with therapeutic use of repaglinide

Authors: Philippe Hantson, Souleiman El Balkhi, Vincent Haufroid, Pierre-François Laterre

Published in: Acta Diabetologica | Issue 6/2020

Excerpt

Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose levels in diabetic patients. It has a favorable safety profile with a low risk of hypoglycemia. Prolonged hypoglycemia appears exceptional due to the short serum elimination half-life. …

Marbury TC, Ruckle JL, Hatorp V, Nielsen KK, Huang WC, Strange P (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67:7–15CrossRef

Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human biotransformation of the insulin secretagogue repaglinide. Br J Pharmacol 56:305–314CrossRef

Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380–387CrossRef

Tomalik-Scharte D, Fuhr U, Hellmich M et al (2011) Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 39:927–932CrossRef

Wei Y, Lin FJ, Lin SY, Wang CC (2019) Risk of hypoglycemia and concomitant use of repaglinide and clopidogrel: a population-based nested case-control study. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1556 CrossRefPubMedPubMedCentral

Title: Sustained hypoglycemia with therapeutic use of repaglinide
Authors: Philippe Hantson
Souleiman El Balkhi
Vincent Haufroid
Pierre-François Laterre
Publication date: 01-06-2020
Publisher: Springer Milan
Keywords: Colchicine
Insulins
Clopidogrel
Metformin
Repaglinide
Hypoglycemia
Insulins
Published in: Acta Diabetologica / Issue 6/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01456-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study

Reply to Tomoyuki Kawada: “Physical activity and risk of diabetic retinopathy: a risk assessment”

A rare missense variant in the milk fat globule-EGF factor 8 (MFGE8) increases T2DM susceptibility and cardiovascular disease risk with population-specific effects

Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks

Physical activity and risk of diabetic retinopathy: a risk assessment

Evaluating the correlation of the impairment between skeletal muscle and heart using MRI in a spontaneous type 2 diabetes mellitus rhesus monkey model

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials